Paroxetine in the first trimester and the prevalence of congenital malformations

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 10, 2007, Pages 1075-1085

  Cole, J Alexander ^a,c,d   Ephross, Sara A ^b   Cosmatos, Irene S ^b   Walker, Alexander M ^a  

^a i3 Drug Safety   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Genzyme Corporation ^*  (United States)

^d GENZYME CORPORATION   (United States)

Author keywords

Antidepressants; Cardiovascular malformations; Congenital malformations; First trimester; Insurance claims; Odds ratio; Paroxetine; Pregnancy; Prevalence; Teratogen

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; ETHINYLESTRADIOL PLUS NORGESTIMATE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; LEVOTHYROXINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PHENYTOIN; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BONE MALFORMATION; CARDIOVASCULAR MALFORMATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; EAR MALFORMATION; EYE MALFORMATION; FACE MALFORMATION; FEMALE; FETAL ALCOHOL SYNDROME; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL MALFORMATION; HEALTH INSURANCE; HUMAN; INFANT; LIVE BIRTH; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL RECORD REVIEW; MOUTH MALFORMATION; NERVOUS SYSTEM MALFORMATION; PERINATAL DRUG EXPOSURE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT MALFORMATION; TERATOGENICITY; UNITED STATES; UROGENITAL TRACT MALFORMATION;

ABNORMALITIES, DRUG-INDUCED; ADULT; CARDIOVASCULAR ABNORMALITIES; COHORT STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; MALE; ODDS RATIO; PAROXETINE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREVALENCE; SEROTONIN UPTAKE INHIBITORS;

EID: 35648959287     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1463     Document Type: Article

References (18)

1. GlaxoSmithKline. Paroxetine [package insert]. Research Triangle Park: NC, 2005.
2. FDA Advising of Risk of Birth Defects with Paxil. Available at http://www.fda.gov/bbs/topics/NEWS/2005/NEW01270.html [Accessed January 4], 2006.
3. Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007; 16: 474-484.
4. Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ 2005; 173: 1320-1321.
5. Unfred CL, Chambers CD, Felix R, Kao K, Dick L, Alvarado S. Birth outcomes among pregnant women taking paroxetine (Paxil). Teratology 2001; 63.
6. Kallen B, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79: 301-308.
7. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reprod Toxicol 2005; 20: 459.
8. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol 2005; 106: 1289-1296.
9. Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 2000; 9: 549-556.
10. Briggs GG. Drug effects on the fetus and breast-fed infant. Clin Obstet Gynecol 2002; 45: 6-21.
11. Cunningham FG, Williams JW. Williams Obstetrics. McGraw-Hill: New York, 2001; x: 1668.
12. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338: 1128-1137.
13. Appendix A. Teratology 2000; 61: 159-160.
14. Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 1999; 59: 1-2.
15. Rothman KJ. Episheet. Available at http://members.aol.com/kruthman/ episheet.xls [Accessed June 1], 2004.
16. Rothman KJ, Boice JD. Epidemiologic Analysis With a Programmable Calculator. U.S. Dept. of Health Education and Welfare Public Health Service National Institutes of Health: Bethesda, MD. Washington, 1979; vii, 142.
17. Hallberg P, Sjöblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast feeding: a review and clinical aspects. J Clin Psychopharmacol 2005; 25: 59-73.
18. Lammer EJ, Chert DT, Noar RM, et al. Retinoic acid embryopathy. NEJM 1985; 313: 837-841.